Peptide research in disagreement | peptideresearchalliance
A growth-hormone pulse, a meal after bowel surgery, a coenzyme among peptides. I’d put the failed bowel-surgery trial on the agenda first.
Ipamorelin after surgery
The ipamorelin trial asks when somebody can eat after bowel surgery. That is an unusually ordinary question for a compound surrounded by talk of growth hormone, recovery and rejuvenation. It is also a question a clinical trial can actually test.
In a randomized trial involving 114 adults undergoing bowel resection, the median time to the first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo. The difference failed the trial’s test of statistical significance, with p=0.15. Its primary endpoint was missed. The result leaves an appealing biological argument unresolved in people.
I’d seat that disappointing meal at the head of the table. An alliance built around promising compounds needs somebody willing to bring the awkward result. Ipamorelin’s human studies deserve at least as much attention as its reputation.
Let an awkward result join the discussion. I trust the conversation more when it can.
The company these compounds make
Peptides are short chains of amino acids. That family resemblance gets retatrutide, BPC-157, ipamorelin and PT-141 into the same conversation, although their targets and histories are strikingly different. NAD+ enters as a coenzyme, a molecule that helps enzymes do their work, with an overlapping audience rather than a peptide structure.
Retatrutide offers substantial weight-loss results from human trials. BPC-157 offers a much larger animal literature than human one. Ipamorelin brings a measurable hormone response and that unsuccessful bowel-surgery trial. PT-141 brings an approved indication with a carefully limited population. NAD+ brings evidence that a blood measurement can rise while the larger longevity question remains open.
Putting them together makes the differences harder to overlook. I’m happy for a useful finding to arrive from any of them; I’m much less happy when a favorable result for one becomes an advertisement for the whole company.
Where the arguments lead
For the most arresting human weight-loss figure, start with retatrutide’s obesity trial. For the question of how often a finding has been reproduced elsewhere, go to BPC-157. PT-141 has the most complete drug-development story here, including the inconvenience of a benefit that comes with substantial nausea. NAD+ raises a different question: exactly which molecule was given, and what changed afterward?
The comparison brings those arguments together. There is no sensible overall winner between a coenzyme, a proposed repair peptide and a drug studied for low sexual desire. Their purposes differ. A shared audience is plenty of reason to discuss them together; it gives them no shared entitlement to trust.
I’d celebrate a convincing controlled human repair trial for BPC-157, or durable health outcomes from NAD+ precursor research. Until then, the small BPC-157 human record and limited clinical effects in the NAD+ review are interesting in their own right. Neither needs embellishment.